MedTrace Logo

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

NCT01390571 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2018-02-05

No results posted yet for this study

Summary

RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Olaparib may help temozolomide kill more tumor cells by making tumor cells more sensitive to the drug.

PURPOSE: This phase I trial is studying the side effects and best dose of olaparib and temozolomide in treating patients with relapsed glioblastoma.

Conditions

Interventions

DRUG

olaparib

DRUG

temozolomide

GENETIC

gene expression analysis

GENETIC

protein expression analysis

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

diffusion-weighted magnetic resonance imaging

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

PROCEDURE

therapeutic conventional surgery

Sponsors & Collaborators

Principal Investigators

  • Anthony Chalmers, Prof · Beatson West of Scotland Cancer Centre

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2017-06-20
Completion
2017-06-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01390571 on ClinicalTrials.gov